Metoprolol Medreg

Metoprolol Tartrate, the active ingredient in Metoprolol Medreg, is a beta blocker presented as an oral tablet for oral use. It treats hypertension, angina pectoris, post‑myocardial infarction and chronic heart failure in adult patients. The product is manufactured to EU standards and is marketed as a generic option for cardiovascular therapy.

GNH USA supplies Metoprolol Medreg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Medreg is a selective β1‑adrenergic antagonist used in several cardiovascular conditions.

- Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion. - Post‑myocardial infarction: improves survival by reducing arrhythmias and recurrent ischemic events. - Chronic heart failure: enhances ventricular function and decreases hospitalisation rates.

Metoprolol Medreg may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headedness, especially when standing quickly. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced blood flow to hands and feet. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dropping below 40 bpm. - Heart block: impaired electrical conduction requiring medical attention. - Acute heart failure exacerbation. - Bronchospasm in patients with reactive airway disease. - Hypotension: dangerously low blood pressure.

Before initiating therapy, clinicians should assess patient history and comorbidities.

- Cardiovascular assessment: evaluate for severe bradycardia, heart block, or decompensated heart failure. - Respiratory caution: avoid in patients with asthma or chronic obstructive pulmonary disease unless benefits outweigh risks. - Diabetes monitoring: beta‑blockade may mask hypoglycaemia symptoms. - Concomitant drugs: review for interactions with calcium channel blockers, digoxin, or other antihypertensives. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Metoprolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): profound heart‑rate slowing and AV‑block. - Antidiabetic agents: may mask hypoglycaemia signs.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, risk of toxicity. - NSAIDs: may reduce antihypertensive effect. - Antidepressants (SSRIs, SNRIs): potential for enhanced bradycardia. - Antithyroid drugs: may exacerbate hypothyroid symptoms.